poisar

Stocks · News reference

Lexicon Pharmaceuticals Presents New Data on Sotagliflozin at AHA Scientific Sessions 2026

Fiscal.ai

Lexicon Pharmaceuticals announced new data from two investigator-initiated studies highlighting the cardiovascular effects of its dual SGLT1/2 inhibitor, sotagliflozin.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading